Cited by 313Tryptophan and brain disordersNeuroinflammation and Neurodegeneration MechanismsAmino Acid Enzymes and Metabolism

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.

The kynurenine pathway and neurodegenerative disease

Open access

Maddison, Daniel C., Giorgini, Flaviano·2015·Seminars in Cell & Developmental Biology

DOI 10.1016/j.semcdb.2015.03.002

Open this paper in CoChat — free account

Abstract

Neuroactive metabolites of the kynurenine pathway (KP) of tryptophan degradation have been closely linked to the pathogenesis of several neurodegenerative diseases. Tryptophan is an essential amino acid required for protein synthesis, and in higher eukaryotes is also converted into the key neurotransmitters serotonin and tryptamine. However, in mammals >95% of tryptophan is metabolized through the KP, ultimately leading to the production of nicotinamide adenosine dinucleotide (NAD(+)). A number of the pathway metabolites are neuroactive; e.g. can modulate activity of several glutamate receptors and generate/scavenge free radicals. Imbalances in absolute and relative levels of KP metabolites have been strongly associated with neurodegenerative disorders including Huntington's, Alzheimer's, and Parkinson's diseases. The KP has also been implicated in the pathogenesis of other brain disorders (e.g. schizophrenia, bipolar disorder), as well as several cancers and autoimmune disorders such as HIV. Pharmacological and genetic manipulation of the KP has been shown to ameliorate neurodegenerative phenotypes in a number of model organisms, suggesting that it could prove to be a viable target for the treatment of such diseases. Here, we provide an overview of the KP, its role in neurodegeneration and the current strategies for therapeutic targeting of the pathway.

Integrity signals

Registry

Crossref · 10.1016/j.semcdb.2015.03.002

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,816
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R. M., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,269
The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications
Hilmas, C. J., Pereira, E. F. R., Alkondon, M., Rassoulpour, A., Schwarcz, R. M., & Albuquerque, E. X. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 875
An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid
Perkins, M. N., & Stone, T. W. (1982) · Brain Research · doi:10.1016/0006-8993(82)91048-4 · Cited by 849
Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism
Fukui, S., Schwarcz, R. M., Rapoport, S. I., Takada, Y., & Smith, Q. R. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb03460.x · Cited by 765
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset
The U.S.–Venezuela Collaborative Research Project*, & Wexler, N. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308679101 · Cited by 761
Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751
QUINOLINIC ACID AND KYNURENINE PATHWAY METABOLISM IN INFLAMMATORY AND NON-INFLAMMATORY NEUROLOGICAL DISEASE
Heyes, M. P., Saito, K., Crowley, J. S., DAVIS, L. E., Demitrack, M. A., Der, M. G., Dilling, L. A., Elia, J., Kruesi, M. J. P., Lackner, A. A., et al. (1992) · Brain · doi:10.1093/brain/115.5.1249 · Cited by 684
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
Björkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., André, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C., Soulet, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080178 · Cited by 646
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection
Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., Croitoru‐Lamoury, J., & Brew, B. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00498.x · Cited by 541
Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration
Zwilling, D., Huang, S., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H., Lee, J. H., Truong, J. K., Andrews-Zwilling, Y. S., Hsieh, E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.020 · Cited by 519
Self-citation
Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity.
Takikawa, O., Kuroiwa, T., Yamazaki, F., & Kido, R. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77982-4 · Cited by 472
3‐Hydroxykynurenine, an Endogenous Oxidative Stress Generator, Causes Neuronal Cell Death with Apoptotic Features and Region Selectivity
Okuda, S., Nishiyama, N., Saitō, H., & Katsuki, H. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70010299.x · Cited by 465
Microglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440
NMDA Receptor Blockade by Ketamine Abrogates Lipopolysaccharide-Induced Depressive-Like Behavior in C57BL/6J Mice
Walker, A. K., Budac, D. P., Bisulco, S., Lee, A. W., Smith, R. A., Beenders, B., Kelley, K. W., & Dantzer, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.71 · Cited by 432
Kynurenines in CNS disease: regulation by inflammatory cytokines.
Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409
Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro
Lue, L., Rydel, R. E., Brigham, E. F., Yang, L., Hampel, H. J., Murphy, G. M., Brachova, L., Yan, S., Walker, D. G., Shen, Y., et al. (2001) · Glia · doi:10.1002/glia.1072 · Cited by 392
Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388
On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress
Lugo-Huitrón, R., Blanco-Ayala, T., Ugalde-Muñiz, P., Carrillo-Mora, P., Pedraza-Chaverrí, J., Silva-Adaya, D., Maldonado, P. D., Torres, I., Pinzón, E., Ortiz-Islas, E., et al. (2011) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2011.07.002 · Cited by 346
Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases.
Christen, S., Peterhans, E., & Stocker, R. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2506 · Cited by 341
Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus
Guillemin, G. J., Brew, B. J., Noonan, C. E., Takikawa, O., & Cullen, K. M. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00655.x · Cited by 338
A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease
Giorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C., & Muchowski, P. J. (2005) · Nature Genetics · doi:10.1038/ng1542 · Cited by 331
Self-citation
Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes
Tavares, R. G., Tasca, C. I., Santos, C. E. S., Alves, L. B., Porciúncula, L. O., Emanuelli, T., & Souza, D. O. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(01)00133-4 · Cited by 320
l-Kynurenine Its synthesis and possible regulatory function in brain
G�l, E. M., & Sherman, A. D. (1980) · Neurochemical Research · doi:10.1007/bf00964611 · Cited by 318
Kynurenine pathway abnormalities in Parkinson's disease
Ogawa, T., Matson, W. R., Beal, M. F., Myers, R. H., Bird, E. D., Milbury, P. E., & Saso, S. (1992) · Neurology · doi:10.1212/wnl.42.9.1702 · Cited by 317
Tryptophan metabolism and oxidative stress in patients with Huntington's disease
Stoy, N., Mackay, G. M., Forrest, C., Christofides, J., Egerton, M., Stone, T., & Darlington, L. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03070.x · Cited by 315
Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine.
Okuda, S., Nishiyama, N., Saitō, H., & Katsuki, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12553 · Cited by 302
Kynurenine and its metabolites in Alzheimer's disease patients
Gulaj, E., Pawlak, K., Bień, B., & Pawlak, D. (2010) · Advances in Medical Sciences · doi:10.2478/v10039-010-0023-6 · Cited by 289
Quinolinic acid is a potent lipid peroxidant in rat brain homogenates
Rı́os, C., & Santamarı́a, A. (1991) · Neurochemical Research · doi:10.1007/bf00966592 · Cited by 272
The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease
Campesan, S., Green, E. W., Breda, C., Sathyasaikumar, K. V., Muchowski, P. J., Schwarcz, R. M., Kyriacou, C. P., & Giorgini, F. (2011) · Current Biology · doi:10.1016/j.cub.2011.04.028 · Cited by 261
Self-citation
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease
GUIDETTI, P., Luthi‐Carter, R., Augood, S. J., & Schwarcz, R. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.006 · Cited by 259
The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
Rahman, A., Ting, K., Cullen, K. M., Braidy, N., Brew, B. J., & Guillemin, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006344 · Cited by 257
Mechanism for Quinolinic Acid Cytotoxicity in Human Astrocytes and Neurons
Braidy, N., Grant, R., Adams, S., Brew, B., & Guillemin, G. (2009) · Neurotoxicity research · doi:10.1007/s12640-009-9051-z · Cited by 234
Expression of The Kynurenine Pathway Enzymes in Human Microglia and Macrophages
Guillemin, G. J., Smith, D. G., Smythe, G. A., Armati, P. J., & Brew, G. J. (2003) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0135-0_12 · Cited by 229
Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl
Behan, W. M. H., McDonald, M., Darlington, L. G., & Stone, T. W. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702940 · Cited by 225
Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN-γ?
Connor, T. J., Starr, N., O’Sullivan, J. B., & Harkin, A. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.007 · Cited by 222
Synthesis and Biochemical Evaluation ofN-(4-Phenylthiazol-2-yl)benzenesulfonamides as High-Affinity Inhibitors of Kynurenine 3-Hydroxylase
Röver, S., Cesura, A. M., Huguenin, P. N., Kettler, R., & Szente, A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970467t · Cited by 212
3-Hydroxykynurenine and 3-Hydroxyanthranilic Acid Generate Hydrogen Peroxide and Promote α-Crystallin Cross-Linking by Metal Ion Reduction
Goldstein, L. E., Leopold, M. C., Huang, X., Atwood, C., Saunders, A. J., Hartshorn, M. A., Lim, J. T., Faget, K. Y., Muffat, J., Scarpa, R. C., et al. (2000) · Biochemistry · doi:10.1021/bi992997s · Cited by 212
Distinct neuroinflammatory profile in post-mortem human Huntington's disease
Silvestroni, A., Faull, R. L. M., Strand, A. D., & Möller, T. (2009) · Neuroreport · doi:10.1097/wnr.0b013e32832e34ee · Cited by 206
Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation
van der Goot, A. T., Zhu, W., Vázquez‐Manrique, R. P., Seinstra, R. I., Dettmer, K., Michels, H., Farina, F., Krijnen, J., Melki, R., Buijsman, R. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203083109 · Cited by 199
On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds
Foster, A. C. (1983) · Neuropharmacology · doi:10.1016/0028-3908(83)90221-6 · Cited by 194
Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice
Lapin, I. P. (1978) · Journal of Neural Transmission · doi:10.1007/bf01262727 · Cited by 193
Quinolinic Acid, an Endogenous Molecule Combining Excitotoxicity, Oxidative Stress and Other Toxic Mechanisms
de la Cruz, V. P., Carrillo-Mora, P. U., & Santamarı́a, A. (2012) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s8158 · Cited by 193
3‐Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum
Guidetti, P., & Schwarcz, R. M. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00806.x · Cited by 180
Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system
Whetsell, W. O., & Schwarcz, R. M. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90609-5 · Cited by 176
Increased neopterin production and tryptophan degradation in advanced Parkinson's disease.
Widner, B., Leblhuber, F., & Fuchs, D. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200014 · Cited by 171
A mechanism of quinolinic acid formation by brain in inflammatory neurological disease: Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate
Heyes, M. P., Saito, K., Major, E. O., Milstien, S., Markey, S. P., & Vickers, J. H. (1993) · Brain · doi:10.1093/brain/116.6.1425 · Cited by 171
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
Guidetti, P., Bates, G. P., Graham, R. K., Hayden, M. R., Leavitt, B. R., MacDonald, M. E., Slow, E., Wheeler, V. C., Woodman, B., & Schwarcz, R. M. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.011 · Cited by 166
Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease
Ting, K. K., Brew, B. J., & Guillemin, G. J. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-36 · Cited by 166
Aβ1-42 induces production of quinolinic acid by human macrophages and microglia
Guillemin, G. J., Smythe, G. A., Veas, L. A., Takikawa, O., & Brew, B. J. (2003) · Neuroreport · doi:10.1097/00001756-200312190-00005 · Cited by 141
Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimer’s disease patients from controls
Schwarz, M., Guillemin, G. J., Teipel, S. J., Büerger, K., & Hampel, H. J. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0384-x · Cited by 141
Targeted Deletion of Kynurenine 3-Monooxygenase in Mice
Giorgini, F., Huang, S.-Y., Sathyasaikumar, K. V., Notarangelo, F. M., Thomas, M. A. R., Tararina, M. A., Wu, H., Schwarcz, R. M., & Muchowski, P. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.503813 · Cited by 138
Self-citation
Targets for future clinical trials in Huntington's disease: What's in the pipeline?
Wild, E. J., & Tabrizi, S. J. (2014) · Movement Disorders · doi:10.1002/mds.26007 · Cited by 135
Structural basis of kynurenine 3-monooxygenase inhibition
Amaral, M., Levy, C., Heyes, D. J., Lafite, P., Outeiro, T. F., Giorgini, F., Leys, D., & Scrutton, N. S. (2013) · Nature · doi:10.1038/nature12039 · Cited by 134
Self-citation
Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases
Jauch, D., Urbańska, E. M., Guidetti, P., Bird, E. D., Vonsattel, J., Whetsell, W. O., & Schwarcz, R. M. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)00280-2 · Cited by 127
MK-801, an receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum
Santamarı́a, A., & Rı́os, C. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90796-n · Cited by 126
Synthesis of Quinolinic Acid by 3‐Hydroxyanthranilic Acid Oxygenase in Rat Brain Tissue In Vitro
Foster, A. C., White, R. J., & Schwarcz, R. M. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb02826.x · Cited by 126
Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease
Bonda, D., Mailankot, M., Stone, J. G., Garrett, M. R., Staniszewska, M. M., Castellani, R. J., Siedlak, S. L., Zhu, X., Lee, H., Perry, G. L., et al. (2010) · Redox Report · doi:10.1179/174329210x12650506623645 · Cited by 126
Importance of the Two Interferon-stimulated Response Element (ISRE) Sequences in the Regulation of the Human Indoleamine 2,3-Dioxygenase Gene
Konan, K. V., & Taylor, M. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19140 · Cited by 121
Uptake of Kynurenine into Rat Brain Slices
Speciale, C., & Schwarcz, R. M. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb13296.x · Cited by 106
Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine
Molteni, R., Macchi, F., Zecchillo, C., Dell’Agli, M., Colombo, E., Calabrese, F., Guidotti, G., Racagni, G., & Riva, M. A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.008 · Cited by 106
Brain‐Specific Modulation of Kynurenic Acid Synthesis in the Rat
Gramsbergen, J. B., Hodgkins, P., Rassoulpour, A., Turski, W. A., Guidetti, P., & Schwarcz, R. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010290.x · Cited by 105
In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain.
Leipnitz, G., Schumacher, C., Dalcin, K. B., Scussiato, K., Solano, A., Funchal, C., Dutra-filho, C., Wyse, A., Wannmacher, C., Latini, A., et al. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.04.017 · Cited by 104
Quinolinic acid — Iron(II) complexes: Slow autoxidation, but enhanced hydroxyl radical production in the Fenton reaction
Plátenı́k, J., Stopka, P., Vejražka, M., & Štípek, S. (2001) · Free Radical Research · doi:10.1080/10715760100300391 · Cited by 100
Histone Deacetylase Inhibition Modulates Kynurenine Pathway Activation in Yeast, Microglia, and Mice Expressing a Mutant Huntingtin Fragment
Giorgini, F., Möller, T., Kwan, W., Zwilling, D., Wacker, J. L., Hong, S. Y., Tsai, L. L., Cheah, C. S., Schwarcz, R. M., Guidetti, P., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708192200 · Cited by 97
Self-citation
The effect of quinolinate on rat brain lipid peroxidation is dependent on iron
Štípek, S., Šťastný, F., Plátenı́k, J., Crkovska, J., & Zima, T. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(97)90002-4 · Cited by 97
Electrochemical and in vitro evaluation of the redox-properties of kynurenine species
Giles, G. I., Collins, C. A., Stone, T. W., & Jacob, C. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02917-0 · Cited by 96
Characterisation of the major autoxidation products of 3-hydroxykynurenine under physiological conditions
Vazquez, S., Garner, B., Sheil, M. M., & Truscott, R. J. W. (2000) · Free Radical Research · doi:10.1080/10715760000300021 · Cited by 94
Antioxidant treatment protects striatal neurons against excitotoxic insults
Nakao, N., Grasbon-Frodl, E. M., Widner, H., & Brundin, P. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00034-6 · Cited by 90
The IDO Inhibitor Coptisine Ameliorates Cognitive Impairment in a Mouse Model of Alzheimer's Disease
Yu, D., Tao, B.-B., Yang, Y.-Y., Du, L., Yang, S.-S., He, X.-J., Zhu, Y., Yan, J., & Yang, Q. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140414 · Cited by 88
Oren-gedoku-to and its Constituents with Therapeutic Potential in Alzheimer's Disease Inhibit Indoleamine 2, 3-Dioxygenase Activity In Vitro
Yu, C.-J., Zheng, M., Kuang, C., Huang, W., & Yang, Q. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100684 · Cited by 85
Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase.
Rafice, S. A., Chauhan, N., Efimov, I., Basran, J., & Raven, E. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370408 · Cited by 83
Blood levels of kynurenines, interleukin‐23 and soluble human leucocyte antigen‐G at different stages of Huntington’s disease
Forrest, C., Mackay, G. M., Stoy, N., Spiden, S. L., Taylor, R., Stone, T. W., & Darlington, L. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06442.x · Cited by 83
Quinolinic acid phosphoribosyltransferase in human and rat brain: Activity in Huntington's disease and in quinolinate-lesioned rat striatum
Foster, A. C., Whetsell, W. O., Bird, E. D., & Schwarcz, R. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90647-x · Cited by 82
Tissue expression and biochemical characterization of human 2‐amino 3‐carboxymuconate 6‐semialdehyde decarboxylase, a key enzyme in tryptophan catabolism
Pucci, L., Perozzi, S., Cimadamore, F., Orsomando, G., & Raffaelli, N. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05635.x · Cited by 78
Heme: A Regulator of Rat Hepatic Tryptophan 2,3-Dioxygenase?
Ren, S., & Correia, M. A. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1755 · Cited by 76
DYSFUNCTIONAL KYNURENINE PATHWAY METABOLISM IN THE R6/2 MOUSE MODEL OF HUNTINGTON’S DISEASE
Sathyasaikumar, K. V., Stachowski, E. K., Amori, L., Guidetti, P., Muchowski, P., & Schwarcz, R. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06675.x · Cited by 72
Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway.
Dang, Y.-H., Dale, W. E., & Brown, O. R. (2000) · Free Radical Biology & Medicine · doi:10.1016/s0891-5849(99)00272-5 · Cited by 72
Nitric oxide synthase inhibition prevents acute quinolinate-induced striatal neurotoxicity
Pérez-Severiano, F., Escalante, B., & Ríos, C. (1998) · Neurochemical Research · doi:10.1023/a:1020700401678 · Cited by 68
Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease
Toledo, L. M., Prime, M. E., Mrzljak, L., Beconi, M. G., Beresford, A. P., Brookfield, F. A., Brown, C. J., Cardaun, I., Courtney, S. M., Dijkman, U., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501350y · Cited by 67
Structural and functional analyses of human tryptophan 2,3-dioxygenase
Meng, B., Wu, D., Gu, J., Ouyang, S., Ding, W., & Liu, Z. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24653 · Cited by 60
Proinflammatory cytokine interferon‐γ increases induction of indoleamine 2,3‐dioxygenase in monocytic cells primed with amyloid β peptide 1–42: implications for the pathogenesis of Alzheimer’s disease
Yamada, A., Akimoto, H., Kagawa, S., Guillemin, G. J., & Takikawa, O. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06175.x · Cited by 58
5-Hydroxyanthranilic Acid, a Tryptophan Metabolite, Generates Oxidative Stress and Neuronal Death via p38 Activation in Cultured Cerebellar Granule Neurones
Smith, A. J., Smith, R. A., & Stone, T. W. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9034-0 · Cited by 58
Expression analysis of novel striatal-enriched genes in Huntington disease
Mazarei, G., Neal, S. J., Bečanović, K., Luthi‐Carter, R., Simpson, E. M., & Leavitt, B. R. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp527 · Cited by 56
Superoxide dismutase enhances the formation of hydroxyl radicals in the reaction of 3-hydroxyanthranilic acid with molecular oxygen
Iwahashi, H., Ishii, T., Sugata, R., & Kido, R. (1988) · Biochemical Journal · doi:10.1042/bj2510893 · Cited by 56
Biochemical mechanisms leading to tryptophan 2,3‐dioxygenase activation
Li, J. S., Han, Q., Fang, J., Rizzi, M., James, A. A., & Li, J. (2007) · Archives of Insect Biochemistry and Physiology · doi:10.1002/arch.20159 · Cited by 52
Effect of kynurenine 3‐hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys
Samadi, P., Grégoire, L., Rassoulpour, A., Guidetti, P., Izzo, E., Schwarcz, R. M., & Bédard, P. J. (2005) · Movement Disorders · doi:10.1002/mds.20596 · Cited by 50
The Janus faces of 3-hydroxykynurenine: Dual redox modulatory activity and lack of neurotoxicity in the rat striatum
Colín-González, A. L., Maya-López, M., Pedraza‐Chaverrí, J., Ali, S. F., Chavarría, A., & Santamarı́a, A. (2014) · Brain Research · doi:10.1016/j.brainres.2014.09.034 · Cited by 46
The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease
Amaral, M., Outeiro, T. F., Scrutton, N. S., & Giorgini, F. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1046-9 · Cited by 46
Self-citation
Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain
Rassoulpour, A., Wu, H.-Q., Pöeggeler, B., & Schwarcz, R. M. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00577-0 · Cited by 42
On the Production and Disposition of Quinolinic Acid in Rat Brain and Liver Slices
Speciale, C., & Schwarcz, R. M. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb05840.x · Cited by 42
The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain
Mazarei, G., Budac, D. P., Lu, G., Lee, H., Möller, T., & Leavitt, B. R. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.08.007 · Cited by 36
Metabolism and Pharmacokinetics of JM6 in Mice: JM6 Is Not a Prodrug for Ro-61-8048
Beconi, M. G., Yates, D., Lyons, K. A., Matthews, K. L., Clifton, S., Mead, T. L., Prime, M. E., Winkler, D. F. H., O'Connell, C., Walter, D. S., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.046532 · Cited by 36
Up-regulation of the brain indoleamine 2,3-dioxygenase activity in a mouse model of Alzheimer's disease by systemic endotoxin challenge
Akimoto, H., Yamada, A., & Takikawa, O. (2007) · International Congress Series · doi:10.1016/j.ics.2007.07.026 · Cited by 9

Flagged first, then by citations

Sorted by citations

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates
Franceschi, C., Garagnani, P., Morsiani, C., Conte, M., Santoro, A., Grignolio, A., Monti, D., Capri, M., & Salvioli, S. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00061 · Cited by 945
NAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790
The kynurenine pathway: a finger in every pie
Savitz, J. B. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0414-4 · Cited by 805
The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease
Yang, T., Richards, E. M., Pepine, C. J., & Raizada, M. K. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0018-2 · Cited by 753

See all 313

Authors: Maddison, D. C., & Giorgini, F.
Affiliations: University of Leicester (GB)
Corresponding author: Giorgini, Flaviano
ORCID: Maddison, Daniel C.
Giorgini, Flaviano
Venue: Seminars in Cell & Developmental Biology
Publisher: Elsevier BV
Published: 2015-04
Volume: 40
Pages: 134-141
ISSN: 1084-9521 (ISSN-L)
DOI: 10.1016/j.semcdb.2015.03.002
OpenAlex: W1990201789
Cited by: 309
References: 94
Citations by year: 2026: 17 · 2025: 31 · 2024: 29 · 2023: 30 · 2022: 32 · 2021: 47 · 2020: 33 · 2019: 27 · 2018: 19 · 2017: 21 · 2016: 17 · 2015: 6
FWCI: 1.20
Type: journal article
Language: en
Open access: green
figshare.com
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Seminars in Cell and Developmental Biology (publishedVersion)
PubMed (publishedVersion)
Figshare (submittedVersion, cc-by)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
Funders: the Midlands Integrative Biosciences Training Partnership (MIBTP)
the Biotechnology and Biological Sciences Research Council (BBSRC)
the Medical Research Council (MRC)
the CHDI Foundation
Topics: Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords: kynurenine pathway, tryptophan metabolism, neurodegenerative diseases, NAD biosynthesis, kynurenine metabolites, glutamate receptors, free radicals, Huntington's disease, Alzheimer's disease, Parkinson's disease, schizophrenia, bipolar disorder, HIV, therapeutic targeting, neuroactive metabolites
MeSH terms: Animals, Humans, Kynurenine, Tryptophan, Neurodegenerative Diseases, Metabolic Networks and Pathways

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The kynurenine pathway and neurodegenerative disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks